ArticleHormones (Athens, Greece)2026
A synergistic drug combination that aids our battle against anaplastic thyroid carcinoma: a case report and discussion.
Article in Hormones (Athens, Greece), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnaplastic thyroid carcinoma (ATC) is a rare and highly aggressive malignancy historically associated with a poor prognosis and a median survival of only 3.16 months. However, recent advances in molecular profiling and immunotherapy are improving outcomes. CASE PRESENTATION: We report the case of a 68-year-old man diagnosed with stage IVC ATC who achieved sustained disease stabilisation and long-term survival. Initial treatment with chemotherapy and radiotherapy led to partial remission of the primary tumour, although there was progression of metastatic disease. The patient was subsequently enrolled in a clinical trial investigating an anti-PD-L1 antibody with positive test results, followed by treatment with pembrolizumab. The latter resulted in nearly 11 years of disease control without significant adverse effects, an exceptional outcome in the context of ATC.
conclusionThis case underscores the transformative potential of immunotherapy in the management of advanced ATC and highlights the importance of continued research into combinatorial therapeutic strategies and predictive biomarkers to optimise treatment outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.